Superworth

Entrada Therapeutics profit margin TRDA

Gross, operating and net profit as a share of revenue over the last twelve months, from 2023.

Net margin, 12 months
n/m
not a meaningful number
Peer median
11.6%

Entrada Therapeutics' net margin works out at −3538% over the last twelve months, but it is not a meaningful number: a margin outside minus 100% to 100% is moved by items that are not sales.

Profit margin over time

OperatingNet

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearNet marginOperating margin
FY2025n/an/a
FY202431.1%22.3%
FY2023−5.2%−2.5%
FY2022n/an/a
FY2021n/an/a
FY2020n/an/a

Quarter by quarter

QuarterEndedNet margin, 12 monthsChange on a yearOperating margin
Q2 FY26n/an/an/a
Q1 FY26n/an/an/a
Q4 FY25n/an/an/a
Q3 FY25n/an/an/a
Q2 FY25−92.3%−135.9 ptsn/a
Q1 FY2514.4%−0.0 pts2.4%
Q4 FY2431.1%+36.3 pts22.3%
Q3 FY2425.5%n/a26.8%
Q2 FY2443.6%n/a39.0%
Q1 FY2414.4%n/a14.6%
Q4 FY23−5.2%n/a−2.5%
Q3 FY23n/an/an/a

Against its peers

Companies in Drug Manufacturers - General nearest Entrada Therapeutics' size, closest first, today.

CompanyProfit margin
TRDAEntrada Therapeuticsn/m
NATRNatures Sunshine Products3.7%
LFVNLifevantage2.8%
SPROSpero Therapeutics15.7%
ARVNArvinas2.9%
PBYIPuma Biotechnology11.6%
IRWDIronwood Pharmaceuticals33.4%
ZVRAZevra Therapeutics42.8%
CRMDCorMedix40.5%
ATNMActinium Pharmaceuticalsn/m
COLLCollegium Pharmaceutical5.9%
Peer median11.6%

What the profit margin tells you

Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).

Compare within an industry. 10% is superb for a retailer and poor for a software company.

More on Entrada Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.